全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Kidney Transplantation from Donors with Severe Disseminated Intravascular Coagulation

DOI: 10.5402/2013/646310

Full-Text   Cite this paper   Add to My Lib

Abstract:

Disseminated intravascular coagulation (DIC) is a syndrome characterized by massive formation of thrombin, which can lead to renal dysfunction or failure. Many transplant centers are reluctant to accept the kidneys from donors with DIC especially if renal dysfunction is present. We developed protocol of machine perfusion followed by tissue plasminogen activator (tPA) infusion in order to treat and evaluate DIC kidneys prior to transplantation. The kidneys were placed on machine preservation with tPA added to the perfusate prior to transplantation. Three kidneys were transplanted from two donors who sustained gunshot injuries to the brain. A biopsy at the time of organ recovery documented widespread fibrin thrombi in approximately 80% of the glomeruli. Serial biopsies showed interval improvement following machine perfusion and a normal appearing kidney three months after successful transplantation. The histological presence of DIC in a deceased organ donor, even if associated with renal dysfunction, is not a contraindication to renal transplantation. Machine perfusion and tPA infusions may contribute to the recovery and successful transplantation of such kidneys. 1. Introduction In the 1970s, several authors observed an association of traumatic brain injury and disseminated intravascular coagulation (DIC), a syndrome characterized by massive formation of thrombin [1, 2]. When the circulation is exposed to large amounts of tissue factor, coagulopathy may develop resulting in widespread deposition of intravascular fibrin and ultimately leading to thrombosis of small and midsize vessels. The spectrum of DIC can range from laboratory abnormalities of no clinical significance, including decrease in platelet count and prolongation of clotting time, to fulminant activation of clotting cascade with multiple organ failure [3]. Clinical manifestations of DIC are variable and may include petechiae, purpura and other signs of abnormal bleeding, fever, hypotension, proteinuria, and hypoxia. Microvascular thrombosis can result in cardiac, pulmonary, renal, hepatic, and CNS dysfunction [4]. Establishing the diagnosis of DIC is problematic. The subcommittee on DIC of the International Society of Haemostasis and Thrombosis (ISHT) defined DIC as an acquired syndrome characterized by the intravascular activation of coagulation with loss of localization arising from different causes. It can originate from and cause damage to the microvasculature, which if sufficiently severe can produce organ dysfunction. The ISHT further proposed a simple scoring algorithm using the

References

[1]  M. S. Druskin and R. Drijansky, “Afibrinogenemia with severe head trauma,” JAMA, vol. 219, no. 6, pp. 755–756, 1972.
[2]  S. H. Goodnight, G. Kenoyer, S. I. Rapaport, M. J. Patch, J. A. Lee, and T. Kurze, “Defibrination after brain-tissue destruction: a serious complication of head injury,” The New England Journal of Medicine, vol. 290, no. 19, pp. 1043–1047, 1974.
[3]  M. Levi, “Disseminated intravascular coagulation: what's new?” Critical Care Clinics, vol. 21, no. 3, pp. 449–467, 2005.
[4]  W. F. Baker, “Clinical aspects of disseminated intravascular coagulation: a clinician's point of view,” Seminars in Thrombosis and Hemostasis, vol. 15, no. 1, pp. 1–57, 1989.
[5]  F. B. Taylor, C. H. Toh, W. K. Hoots, H. Wada, and M. Levi, “Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation: on behalf of the scientific subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haematostasis (ISTH),” Thrombosis and Haemostasis, vol. 86, no. 5, pp. 1327–1330, 2001.
[6]  T. R. Hefty, L. W. Cotterell, S. C. Fraser, S. H. Goodnight, and T. R. Hatch, “Disseminated intravascular coagulation in cadaveric organ donors. Incidence and effect on renal transplantation,” Transplantation, vol. 55, no. 2, pp. 442–443, 1993.
[7]  C. J. Wang, S. Shafique, J. McCullagh, D. A. Diederich, F. T. Winklhofer, and J. B. Wetmore, “Implications of donor disseminated intravascular coagulation on kidney allograft recipients,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 5, pp. 1160–1167, 2011.
[8]  M. Pastural, B. Barrou, A. Delcourt, M. O. Bitker, S. Ourahma, and F. Richard, “Successful kidney transplantation using organs from a donor with disseminated intravascular coagulation and impaired renal function: case report and review of the literature,” Nephrology Dialysis Transplantation, vol. 16, no. 2, pp. 412–415, 2001.
[9]  A. M. Meyers, J. Lewin, P. B. Disler, F. J. Milne, P. Hyde, C. Abrahams, et al., “Donor disseminated intravascular coagulation (DIC), intraglomerular fibrin deposition, and subsequent graft function,” Kidney International, vol. 13, article 432, 1978.
[10]  D. D. Nghiem, P. R. Olson, and K. K. Sureshkumar, “Role of pulsatile perfusion with tissue plasminogen activator in deceased donor kidneys with extensive glomerular thrombosis,” Transplantation Proceedings, vol. 41, no. 1, pp. 29–31, 2009.
[11]  J. J. T. H. Roelofs, K. M. A. Rouschop, J. C. Leemans et al., “Tissue-type plasminogen activator modulates inflammatory responses and renal function in ischemia reperfusion injury,” Journal of the American Society of Nephrology, vol. 17, no. 1, pp. 131–140, 2006.
[12]  D. Francois and B. Delgrange, “A case of acute renal failure caused by thrombosis of both renal arteries,” Acta Clinica Belgica, vol. 49, no. 3-4, pp. 177–182, 1994.
[13]  W. Zenz, B. Zoehrer, M. Levin et al., “Use of recombinant tissue plasminogen activator in children with meningococcal purpura fulminans: a retrospective study,” Critical Care Medicine, vol. 32, no. 8, pp. 1777–1780, 2004.
[14]  D. C. Rijken, E. Seifried, M. M. Barrett-Bergshoeff, and G. Dooijewaard, “Plasminogen activation at low temperatures in plasma samples containing therapeutic concentrations of tissue-type plasminogen activator or other thrombolytic agents,” Thrombosis and Haemostasis, vol. 64, no. 1, pp. 47–52, 1990.

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133

WeChat 1538708413